



Final Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
4 - 6 November 2008
CCV/CICG, Geneva

Tuesday, 4 November 2008

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	Welcome - introduction		20mn
09:20	Report from IVB Director including status of implementation of recommendations Presentation: J.-M. Okwo-Bele, WHO, 20mn Discussion: 20mn	FOR INFORMATION	40mn
10:00	Priorities, major policy and implementation issues: reports from AMRO, EURO and WPRO Presentation: C. Ruiz-Matus, AMRO, 20mn Discussion: 20mn	FOR INFORMATION & DISCUSSION	2hrs
11:00	Coffee/tea break	Break	30mn
11:30	Priorities, major policy and implementation issues: reports from AMRO, EURO and WPRO (contd.) Presentation: E. Laurent, EURO, 20mn Discussion: 20mn Presentation: Y. Baoping, WPRO, 20mn Discussion: 20mn		
12:30	Lunch	Break	1hr 30mn
14:00	Report from the GAVI secretariat Presentation: Nina Schwalbe, GAVI Alliance, 20mn	FOR INFORMATION	40mn

	Discussion: 20mn		
14:40	Reports from other Advisory Committees in Immunization - Global Advisory Committee on Vaccine Safety (GACVS) report of June 2008 meeting including discussion on crisis management of vaccine safety signals - P.-H. Lambert, Chair of GACVS, 10mn Discussion 10mn - Expert Committee on Biological Standardization (ECBS) report of October 2008 meeting - P. Minor, Chair of ECBS, 10mn Discussion 10mn - Advisory Committee of the Initiative for Vaccine Research (IVAC) report of 2008 meeting - M-P. Kieny, WHO, 10mn Discussion: 10mn	FOR INFORMATION	1hr 30mn
15:40	Coffee/tea break	Break	30mn
16:10	Reports from other Advisory Committees in Immunization (contd.) - Technologies and Logistics Advisory Committee (TLAC) report of first meeting - B. Weniger, Chair of TLAC, 10mn Discussion: 20mn		
16:40	H5N1 influenza vaccine Update on H5N1 influenza epidemiological situation. S. Briand, WHO 10mn Presentation of the SAGE H5N1 Working Group plan of work. S. Chunsuttiwat, SAGE member 10mn Discussion: 40mn	FOR DISCUSSION Presentation of draft working plan for the SAGE Working Group to be reviewed for comments. The work plan will outline the proposed methods and activities the WG will undertake to present evidence to answers to the following questions: What the role can the H5N1 influenza vaccine have in protecting certain populations deemed at risk for acquiring an infection to the H5N1 avian virus and, What can be done with H5N1 influenza vaccine which is reaching the end of its shelf life? The work of the WG is planned to be presented at the next SAGE Meeting, in April 2009.	1hr
18:00	Cocktail		

Wednesday, 5 November 2008

08:30	HPV vaccines Introduction, H. Rees, SAGE member, 5mn HPV-related disease and HPV vaccines. L. Markowitz, US CDC, 25mn Vaccine acceptability and delivery options and global experience. M. Chirenje, University of Zimbabwe, 10mn HPV vaccines: Projected impact, cost-effectiveness, cost, financing, and global policy and opinion. S. de Sanjosé, Institut Catala de Oncologia, 15mn Questions for clarification and discussion: 30mn	FOR DECISION - Recommendation regarding use of HPV vaccines for national immunization programmes.	3hrs
10:00	Coffee/tea break	Break	30mn
10:30	HPV vaccines (contd.) Presentation of candidate recommendations proposed by HVAC. K. Irwin, WHO, 15mn Discussion of candidate recommendations: 1hr and 15mn	FOR DECISION	
12:00	Lunch break	Break	1hr 30mn
13:30	Measles Introduction, H. Bashour, SAGE member, Chair of the SAGE measles Working Group, 5mn Status of global measles control & workplan on feasibility of global measles elimination - A. Dabbagh, WHO, 20mn Discussion: 20mn Progress on policy for introduction of second dose of measles vaccine - R. Hall, Monash University, 20mn Discussion: 55mn	FOR DISCUSSION -Discussion on the proposed workplan on the feasibility of global elimination of measles. -Discussion of the immunological and epidemiological evidence supporting a two dose schedule of measles vaccine. -Discussion on the approach being taken to develop policy options for introduction of a 2nd dose of measles vaccine.	2hrs
15:30	Coffee/tea break	Break	30mn

16:00	Review of updated immunogenicity and efficacy data of rotavirus vaccines Update on rotavirus vaccines introduction and surveillance scale-up C. Mantel, WHO, 10mn Update on rotavirus vaccines immunogenicity and efficacy studies in developing countries and outcome of the Diarrhoeal and Enteric Vaccines Advisory Committee (DEVAC) K. Neuzil, PATH, 25mn Discussion: 55mn	FOR DISCUSSION - Review of updated immunogenicity and efficacy data in support of use of vaccine in other regions than Europe and the Americas. Expected output will depend on evidence reviewed by the diarrhoeal disease advisory committee and conclusions of this committee. This may lead to updating of the vaccine position paper.	1hr 30mn
17:30	End of meeting		

Thursday, 6 November 2008

08:30	Polio eradication Polio Eradication - progress and prospects - B. Aylward, WHO, 15mn Discussion: 15mn Strategies for Overcoming Sub-optimal OPV Efficacy in Northern India, S. Cochi, Chair of ACPE, 25mn Discussion: 25mn Status of polio eradication and action Plan to Overcome Low OPV Coverage During Polio Campaigns in Northern Nigeria, A. Nasidi, Director Public Health, Federal Ministry of Health and Chairman Task Force on Polio Eradication and Routine Immunization, Nigeria, 25mn (via phone connection) Discussion: 25mn Report of the first meeting of the SAGE IPV Working Group - E. Miller, Chair IPV working group, 25mn Discussion: 25mn	FOR DISCUSSION & POSSIBLE DECISION - Risk management for polio eradication and long-term strategies for mitigating post eradication risks including options for IPV use. This will lead to updating the 2003 position paper on IPV and consolidating it with other relevant documents (including the 2006 supplement to the IPV position paper) into one polio vaccines position paper covering both IPV and OPV, including monovalent or bivalent OPVs, and both the pre and post-eradication periods.	3hrs
10:00	Coffee/tea break	Break	30mn

10:30	Polio eradication (contd.)	FOR DISCUSSION & POSSIBLE DECISION	
12:00	Lunch break		30mn
13:30	Beyond hepatitis B vaccine introduction - Establishing disease control goals Hepatitis B working group X. Liang, SAGE member and Chair of Working Group, 10mn Perinatal Prevention: current status and monitoring and scientific basis and prospects for policy A. Hall, London School of Hygiene and Tropical Medicine, 25mn Discussion: 35 mn Setting goals for the prevention of hepatitis B virus transmission J. Ward, US CDC, 15mn Discussion 35mn	FOR DISCUSSION & POSSIBLE DECISION - For discussion: Review WHO recommendations with respect to the use of a birth dose of hepatitis B vaccine, use of a booster and other key recommendations on vaccine use that would need to be updated. This is only for discussions and it is planned that a decision will be asked form SAGE at the April meeting leading to the updating of the hepatitis B vaccine position paper. - For discussion and possibly decision: Update on working group process to review issues related to the establishment of regional or global hepatitis B control goals and outlining aspects of a comprehensive strategy for hepatitis B control.	2hrs
15:30	Coffee/tea break		20mn
16:00	Closing		30mn
16:30	End of meeting		